Results 31 to 40 of about 257,172 (346)

Supervised self-administration of outpatient parenteral antibiotic therapy: a report from a large tertiary hospital in Australia

open access: yesInternational Journal of Infectious Diseases, 2015
Introduction: Outpatient parenteral antibiotic therapy (OPAT) has become established as a standard of care in most Australian hospitals to treat a variety of infections.
S. Subedi   +4 more
doaj   +1 more source

Clinical trial of FK 506 immunosuppression in adult cardiac transplantation [PDF]

open access: yes, 1992
The new immunosuppressive agent FK 506 was used as primary immunotherapy in conjunction with low-dose steroids and azathioprine in 72 patients subsequent to orthotopic cardiac transplantation.
Armitage   +17 more
core   +1 more source

Rapid-onset diabetic ketoacidosis secondary to nivolumab therapy

open access: yesEndocrinology, Diabetes & Metabolism Case Reports, 2018
We report a case of a 67-year-old man with type 2 diabetes presented with diabetic ketoacidosis, two weeks after his first dose of nivolumab therapy for non–small-cell lung carcinoma.
Senhong Lee   +3 more
doaj   +1 more source

From sea to shining IV: the current state of OPAT in the United States

open access: yesTherapeutic Advances in Infectious Disease, 2023
First described in the United States, outpatient parenteral antibiotic therapy (OPAT) has become an indispensable part of treating serious infections. The proportion of infectious disease (ID) physicians utilizing a formal OPAT program has increased in ...
Jeffrey Larnard   +3 more
doaj   +1 more source

Infusion of N‐acetyl cysteine during hypoglycaemia in humans does not preserve the counterregulatory response to subsequent hypoglycaemia

open access: yesEndocrinology, Diabetes & Metabolism, 2020
Aim Administration of N‐acetyl cysteine (NAC) during hypoglycaemia will preserve the counterregulatory response to subsequent hypoglycaemia in healthy humans. Methods This was a randomized double‐blind cross over study where humans were given either a 60‐
Amir Moheet   +5 more
doaj   +1 more source

Home parenteral nutrition with an omega-3-fatty-acid-enriched MCT/LCT lipid emulsion in patients with chronic intestinal failure (the HOME study):study protocol for a randomized, controlled, multicenter, international clinical trial [PDF]

open access: yes, 2019
BACKGROUND: Home parenteral nutrition (HPN) is a life-preserving therapy for patients with chronic intestinal failure (CIF) indicated for patients who cannot achieve their nutritional requirements by enteral intake.
A Van Gossum   +42 more
core   +3 more sources

Effect of acute aerobic exercise before immunotherapy and chemotherapy infusion in patients with metastatic non-small-cell lung cancer: protocol for the ERICA feasibility trial

open access: yesBMJ Open, 2022
Introduction Patients with metastatic non-small cell lung cancer (mNSCLC) suffer from numerous symptoms linked to disease and treatment which may further impair the patient’s overall condition.
Vincent Pialoux   +11 more
doaj   +1 more source

Nitrates for the Management of Acute Heart Failure Syndromes, A Systematic Review [PDF]

open access: yes, 2016
© The Author(s) 2016Intravenous nitrates are widely used in the management of acute heart failure syndrome (AHFS) yet with lack of robust evidence to support their use.
Farag, Mohamed   +2 more
core   +2 more sources

IVsight as an Infusion Monitor for Patients Receiving Intravenous Therapy: An Exploratory, Unblinded, Single-Center Trial

open access: yesCurrent Therapeutic Research
: Background: Intravenous (IV) infusion therapy is commonly used in health care settings. However, IV therapy at home can be challenging because it relies on the patient's ability to manage multiple medications correctly, which may lead to decreased ...
Carlos Mejia-Chew, MD   +7 more
doaj   +1 more source

Outpatient administration of naxitamab in combination with granulocyte‐macrophage colony‐stimulating factor in patients with refractory and/or relapsed high‐risk neuroblastoma: Management of adverse events

open access: yesCancer Reports, 2023
Background Naxitamab is a humanized GD2‐binding monoclonal antibody that received accelerated approval from the U.S. Food and Drug Administration for refractory or relapsed high‐risk neuroblastoma limited to bone or bone marrow.
Jaume Mora   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy